A Phase 4, open-label, single arm, 24-week, phase 4 study to evaluate thesafety and efficacy of Mepolizumab 100 mg SC administered every 4 weeks in Indianparticipants aged =18 years with Severe eosinophilic asthma requiring oral corticosteroidtreatment to Maintain asthma control (PRISM)
100 Clinical Results associated with Glaxosmithkline, Inc. /Mississauga Facility/
0 Patents (Medical) associated with Glaxosmithkline, Inc. /Mississauga Facility/
100 Deals associated with Glaxosmithkline, Inc. /Mississauga Facility/
100 Translational Medicine associated with Glaxosmithkline, Inc. /Mississauga Facility/